Adaptimmune (ADAP) stock price, revenue, and financials

Adaptimmune market cap is $743.2 m, and annual revenue was $3.96 m in FY 2020

$743.2 M

ADAP Mkt cap, 07-May-2021

$434 K

Adaptimmune Revenue Q1, 2021
Adaptimmune Net income (Q1, 2021)-37.8 M
Adaptimmune EBIT (Q1, 2021)-37.9 M
Adaptimmune Cash, 31-Mar-202132.4 M
Adaptimmune EV733.5 M

Adaptimmune Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

158.8m84.0m68.4m50.4m56.9m

Accounts Receivable

149.5k206.0k192.0k139.0k

Prepaid Expenses

21.7m25.8m30.9m29.8m

Inventories

1.4m

Current Assets

198.8m230.2m231.1m120.5m398.2m

PP&E

27.9m40.7m36.1m31.1m27.8m

Total Assets

234.5m281.1m276.7m181.5m451.1m

Accounts Payable

11.4m8.4m4.1m6.4m6.4m

Short-term debt

2.1m2.8m

Current Liabilities

40.3m74.3m24.4m34.3m39.1m

Long-term debt

23.0m20.9m

Total Debt

25.1m23.7m

Total Liabilities

68.4m78.2m29.9m57.9m109.9m

Common Stock

854.0k939.0k943.0k1.3m

Additional Paid-in Capital

341.2m455.4m574.2m585.6m935.7m

Retained Earnings

(161.5m)(231.6m)(318.5m)(455.7m)(585.8m)

Total Equity

166.1m203.0m246.9m123.6m341.2m

Financial Leverage

1.4 x1.4 x1.1 x1.5 x1.3 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

163.8m150.9m140.4m170.6m122.0m145.3m53.4m42.3m153.1m49.9m34.6m39.4m86.4m122.4m78.5m32.4m

Accounts Receivable

1.0k107.0k1.4m4.1m5.1m2.0m3.8m

Prepaid Expenses

12.5m12.3m12.0m19.2m16.3m18.0m28.8m32.6m21.8m32.1m37.9m44.1m31.3m39.1m26.8m41.3m

Current Assets

238.6m218.2m199.5m222.9m237.7m253.9m195.7m161.7m261.6m200.3m175.1m147.0m227.8m458.1m426.7m359.3m

PP&E

13.8m13.4m15.1m35.1m38.9m39.8m41.2m39.5m38.1m35.7m33.7m31.6m28.7m27.0m26.9m27.7m

Total Assets

261.6m239.6m222.6m266.0m284.3m301.4m247.1m211.3m309.6m270.4m239.5m208.3m285.2m512.2m479.0m411.6m

Accounts Payable

2.4m2.5m3.2m5.2m4.6m2.5m5.1m4.1m3.9m5.4m4.3m5.5m7.1m8.8m4.0m4.1m

Short-term debt

1.4m2.6m2.5m2.6m2.8m

Current Liabilities

19.8m20.1m22.7m31.9m30.3m68.6m51.9m42.3m29.6m23.4m28.3m37.4m29.8m38.6m34.9m31.3m

Long-term debt

26.8m23.7m22.6m21.8m20.8m21.1m19.9m

Total Debt

28.2m23.7m22.6m24.4m23.3m23.7m22.7m

Total Liabilities

42.6m42.6m42.6m57.7m54.8m72.4m55.8m46.2m33.5m50.8m52.5m60.6m99.2m104.6m102.8m102.4m

Common Stock

682.0k682.0k682.0k801.0k853.0k854.0k858.0k860.0k939.0k940.0k943.0k943.0k1.1m1.3m1.3m1.3m

Additional Paid-in Capital

334.4m336.9m339.2m405.2m449.0m452.6m461.6m466.2m570.4m577.7m581.2m583.1m678.3m928.8m932.5m941.6m

Retained Earnings

(105.5m)(127.6m)(146.1m)(183.3m)(203.5m)(204.4m)(244.1m)(287.6m)(282.3m)(345.9m)(387.0m)(426.3m)(483.8m)(513.7m)(549.1m)(623.5m)

Total Equity

218.9m197.0m180.0m208.3m229.5m229.0m191.3m165.1m276.2m219.7m187.0m147.7m186.0m407.6m376.2m309.2m

Debt to Equity Ratio

0.1 x0.1 x

Debt to Assets Ratio

0.1 x0.1 x

Financial Leverage

1.2 x1.2 x1.2 x1.3 x1.2 x1.3 x1.3 x1.3 x1.1 x1.2 x1.3 x1.4 x1.5 x1.3 x1.3 x1.3 x

Adaptimmune Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(23.0m)(70.1m)(95.5m)(137.2m)(130.1m)

Depreciation and Amortization

5.4m7.8m8.0m7.6m

Accounts Payable

3.9m

Cash From Operating Activities

(48.2m)(54.3m)(104.4m)(112.5m)(53.6m)

Purchases of PP&E

(24.6m)(3.9m)(1.6m)(2.3m)

Cash From Investing Activities

17.8m(126.1m)(17.5m)94.9m(278.9m)

Cash From Financing Activities

17.0k103.6m102.7m366.0k340.1m

Net Change in Cash

(74.5m)(15.8m)(17.6m)6.6m

Income Taxes Paid

1.6m258.0k201.0k75.0k

Adaptimmune Ratios

USDQ1, 2016

Financial Leverage

1.2 x

Adaptimmune Operating Metrics

FY, 2016

Patent Applications

69

Patents Issued

173

Adaptimmune Employee Rating

3.541 votes
Culture & Values
3.5
Work/Life Balance
3.6
Senior Management
3.2
Salary & Benefits
3.6
Career Opportunities
3.5
Source